Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of down syndrome

The Metabolic and Molecular Bases of Inherited Disease

Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101 · see citing works

MAPK cascade signalling and synaptic plasticity

Thomas, G. M., & Huganir, R. L. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1346 · Cited by 1,454 · see citing works

Mitogen-activated protein kinases in synaptic plasticity and memory

Sweatt, J. D. (2004) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2004.04.001 · Cited by 990 · see citing works

A mouse model for Down syndrome exhibits learning and behaviour deficits

Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913 · see citing works

Recombinant AAV Viral Vectors Pseudotyped with Viral Capsids from Serotypes 1, 2, and 5 Display Differential Efficiency and Cell Tropism after Delivery to Different Regions of the Central Nervous System

Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741 · see citing works

Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome

Fernandez, F., Morishita, W., Zuniga, E., Nguyen, J., Blank, M., Malenka, R. C., & Garner, C. C. (2007) · Nature Neuroscience · doi:10.1038/nn1860 · Cited by 509 · see citing works

Cognitive deficits and associated neurological complications in individuals with Down's syndrome

Lott, I. T., & Dierssen, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70112-5 · Cited by 484 · see citing works

Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome

Kleschevnikov, A. M., Belichenko, P. V., Villar, A. J., Epstein, C. J., Malenka, R. C., & Mobley, W. C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1766-04.2004 · Cited by 459 · see citing works

Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome

Altafaj, X. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.18.1915 · Cited by 396 · see citing works

DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles

Aranda, S., Laguna, A., & de la Luna, S. (2011) · The FASEB Journal · doi:10.1096/fj.10-165837 · Cited by 320 · see citing works

Factors Influencing Recombinant Adeno-Associated Virus Production

Salvetti, A., Orève, S., Chadeuf, G., Favre, D., Chérel, Y., Champion-Arnaud, P., David-Ameline, J., & Moullier, P. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.5-695 · Cited by 241 · see citing works

A behavioral assessment of Ts65Dn mice: a putative Down syndrome model

Escorihuela, R. M., Fernández‐Teruel, A., Vallina, I. F., Baamonde, C., Lumbreras, M., Dierssen, M., Tobeña, A., & Flórez, J. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12052-6 · Cited by 234 · see citing works

Altered long-term potentiation in the young and old Ts65Dn mouse, a model for down syndrome

Siarey, R. J., Stoll, J., Rapoport, S. I., & Galdzicki, Z. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00157-3 · Cited by 222 · see citing works

Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A

Guedj, F., Sebrié, C., Rivals, I., Ledru, A., Paly, E., Bizot, J. C., Smith, D., Rubin, E. M., Gillet, B., Arbonés, M. L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004606 · Cited by 216 · see citing works

Molecular and systems mechanisms of memory consolidation and storage

Wang, H., Hu, Y., & Tsien, J. Z. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.06.004 · Cited by 205 · see citing works

Ca2+-Stimulated Adenylyl Cyclases Regulate ERK-Dependent Activation of MSK1 during Fear Conditioning

Sindreu, C. B., Scheiner, Z. S., & Storm, D. R. (2007) · Neuron · doi:10.1016/j.neuron.2006.11.024 · Cited by 192 · see citing works

Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with down syndrome

Dowjat, W. K., Adayev, T., Kuchna, I., Nowicki, K., Palminiello, S., Hwang, Y. W., & Wegiel, J. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2006.11.026 · Cited by 190 · see citing works

HumanMinibrainHomologue (MNBH/DYRK1): Characterization, Alternative Splicing, Differential Tissue Expression, and Overexpression in Down Syndrome

Guimera, J., Casas, C., Estivill, X., & Pritchard, M. (1999) · Genomics · doi:10.1006/geno.1999.5775 · Cited by 186 · see citing works

Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome

Siarey, R. J., Carlson, E. J., Epstein, C. J., Balbo, A., Rapoport, S. I., & Galdzicki, Z. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00083-0 · Cited by 184 · see citing works

Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells

Yang, E. J., Ahn, Y. S., & Chung, K. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104091200 · Cited by 172 · see citing works

Acute Injections of the NMDA Receptor Antagonist Memantine Rescue Performance Deficits of the Ts65Dn Mouse Model of Down Syndrome on a Fear Conditioning Test

Costa, A. C. S., Scott-McKean, J. J., & Stasko, M. R. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301535 · Cited by 163 · see citing works

Hippocampal hypocellularity in the Ts65Dn mouse originates early in development

Lorenzi, H. A., & Reeves, R. H. (2006) · Brain Research · doi:10.1016/j.brainres.2006.05.022 · Cited by 145 · see citing works

Dyrk1A expression pattern supports specific roles of this kinase in the adult central nervous system

Martı́, E., Altafaj, X., Dierssen, M., de la Luna, S., Fotaki, V., Alvarez, M., Pérez-Riba, M., Ferrer, I., & Estivill, X. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04069-6 · Cited by 136 · see citing works

Dynamin is a minibrain kinase/dual specificity Yak1-related kinase 1A substrate

Chen-Hwang, M.-C., Chen, H.-R., Elzinga, M., & Hwang, Y.-W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111101200 · Cited by 106 · see citing works

Impaired Spatial Learning Strategies and Novel Object Recognition in Mice Haploinsufficient for the Dual Specificity Tyrosine-Regulated Kinase-1A (Dyrk1A)

Arqué, G., Fotaki, V., Fernández, D., de Lagrán, M. M., Arbonés, M. L., & Dierssen, M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002575 · Cited by 97 · see citing works

Caffeine-Mediated Presynaptic Long-Term Potentiation in Hippocampal CA1 Pyramidal Neurons

Martín, E. D., & Buño, W. (2003) · Journal of Neurophysiology · doi:10.1152/jn.00601.2002 · Cited by 94 · see citing works

Memantine Normalizes Several Phenotypic Features in the Ts65Dn Mouse Model of Down Syndrome

Rueda, N., Llorens-Martı́n, M., Flórez, J., Valdizán, E. M., Banerjee, P., Trejo, J. L., & Martínez‐Cué, C. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100240 · Cited by 87 · see citing works

Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome

Siarey, R. J., Kline‐Burgess, A., Cho, M., Balbo, A., Best, T. K., Harashima, C., Klann, E., & Galdzicki, Z. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03971.x · Cited by 86 · see citing works

Behavioral, cognitive and biochemical responses to different environmental conditions in male Ts65Dn mice, a model of Down syndrome

Martínez‐Cué, C., Rueda, N., García, E., Davisson, M. T., Schmidt, C., & Flórez, J. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.04.016 · Cited by 80 · see citing works

Targeting Dyrk1A with AAVshRNA Attenuates Motor Alterations in TgDyrk1A, a Mouse Model of Down Syndrome

Ortiz-Abalia, J., Sahún, I., Altafaj, X., Andreu, N., Estivill, X., Dierssen, M., & Fillat, C. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.09.010 · Cited by 70 · see citing works

Phosphorylation of Amphiphysin I by Minibrain Kinase/Dual-specificity Tyrosine Phosphorylation-regulated Kinase, a Kinase Implicated in Down Syndrome

Murakami, N., Xie, W. Q., Lu, R. C., Chen‐Hwang, M., Wieraszko, A., & Hwang, Y. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513497200 · Cited by 70 · see citing works

Mouse Models of Cognitive Disorders in Trisomy 21: A Review

Sérégaza, Z., Roubertoux, P. L., Jamon, M., & Soumireu-Mourat, B. (2006) · Behavior Genetics · doi:10.1007/s10519-006-9056-9 · Cited by 66 · see citing works

Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801

Siddiqui, A. H., Lacroix, T., Stasko, M. R., Scott-McKean, J. J., Costa, A. C. S., & Gardiner, K. (2008) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2008.00428.x · Cited by 64 · see citing works

MNB/DYRK1A phosphorylation regulates the interactions of synaptojanin 1 with endocytic accessory proteins

Adayev, T., Chen‐Hwang, M., Murakami, N., Wang, R., & Hwang, Y. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.169 · Cited by 57 · see citing works

Gene-dosage effects in Down syndrome and trisomic mouse models.

Gardiner, K. (2004) · Genome biology · doi:10.1186/gb-2004-5-10-244 · Cited by 55 · see citing works

Predicting pathway perturbations in Down syndrome

Gardiner, K. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6721-2_2 · Cited by 33 · see citing works

Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice

Arqué, G., de Lagrán, M. M., Arbonés, M. L., & Dierssen, M. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.027 · Cited by 24 · see citing works

Epigallocatechin‐3‐gallate, a DYRK1A inhibitor, rescues cognitive deficits in D own syndrome mouse models and in humans

de la Torre, R., Sola, S. D., Pons‐Espinal, M., Duchon, A., de Lagrán, M. M., Farré, M., Fitó, M., Benejam, B., Langohr, K., Rodríguez, J. C., et al. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201300325 · Cited by 283 · see citing works

Rodent models in Down syndrome research: impact and future opportunities

Hérault, Y., Delabar, J. M., Fisher, E., Tybulewicz, V. L. J., Yu, E. Y., & Brault, V. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.029728 · Cited by 191 · see citing works

DYRK1A, a dosage-sensitive gene involved in neurodevelopmental disorders, is a target for drug development in down syndrome

Duchon, A., & Herault, Y. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00104 · Cited by 181 · see citing works

DYRK1A and cognition: A lifelong relationship

Arbonés, M. L., Thomazeau, A., Nakano-Kobayashi, A., Hagiwara, M., & Delabar, J. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.010 · Cited by 165 · see citing works

Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview

Lindberg, M. F., & Meijer, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116047 · Cited by 123 · see citing works

Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and Neuromorphological alterations found in a mouse model of down syndrome

García-Cerro, S., Martínez, P., Vidal, V., Corrales, A., Flórez, J., Vidal, R., Rueda, N., Arbonés, M. L., & Martínez-Cué, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106572 · Cited by 104 · see citing works

Prefrontal Deficits in a Murine Model Overexpressing the Down Syndrome Candidate GeneDyrk1a

Thomazeau, A., Lassalle, O., Iafrati, J., Souchet, B., Guedj, F., Janel, N., Chavis, P., Delabar, J. M., & Manzoni, O. J. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2852-13.2014 · Cited by 93 · see citing works

Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn down syndrome mice

Yin, X., Jin, N., Shi, J., Zhang, Y., Wu, Y., Gong, C.-X., Iqbal, K., & Liu, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-00682-y · Cited by 93 · see citing works

Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A

Nguyen, T. L., Duchon, A., Manousopoulou, A., Loaëc, N., Villiers, B., Pani, G., Karatas, M., Mechling, A. E., Harsan, L. A., Limanton, E., et al. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.035634 · Cited by 87 · see citing works

Prenatal pharmacotherapy rescues brain development in a Down’s syndrome mouse model

Guidi, S., Stagni, F., Bianchi, P., Ciani, E., Giacomini, A., Franceschi, M. D., Moldrich, R. X., Kurniawan, N. D., Mardon, K., Giuliani, A., et al. (2013) · Brain · doi:10.1093/brain/awt340 · Cited by 82 · see citing works

Dyrk1a from gene function in development and physiology to dosage correction across life span in down syndrome

Atas-Ozcan, H., Brault, V., Duchon, A., & Herault, Y. (2021) · Genes · doi:10.3390/genes12111833 · Cited by 78 · see citing works

DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome

Féki, A., & Hibaoui, Y. (2018) · Brain Sciences · doi:10.3390/brainsci8100187 · Cited by 71 · see citing works

Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors

Rüben, K., Wurzlbauer, A., Walte, A., Sippl, W., Bracher, F., & Becker, W. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132453 · Cited by 65 · see citing works

Prenatal treatment of Down syndrome

Guedj, F., Bianchi, D. W., & Delabar, J. M. (2014) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000056 · Cited by 62 · see citing works

The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair

Guard, S., Poss, Z., Ebmeier, C., Pagratis, M., Simpson, H., Taatjes, D., & Old, W. (2018) · Scientific Reports · doi:10.1038/s41598-019-42990-5 · Cited by 54 · see citing works

Epigenetics: The neglected key to minimize learning and memory deficits in Down syndrome

Dekker, A. D., Deyn, P. P. D., & Rots, M. G. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.05.004 · Cited by 62 · see citing works

Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes

Stringer, M., Abeysekera, I., Thomas, J. R., LaCombe, J., Stancombe, K., Stewart, R. B., Dria, K. J., Wallace, J. M., Goodlett, C. R., & Roper, R. J. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.05.003 · Cited by 59 · see citing works

Treating enhanced GABAergic inhibition in Down syndrome: Use of GABA α5-selective inverse agonists

Martínez-Cué, C., Delatour, B., & Potier, M.-C. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.12.008 · Cited by 58 · see citing works

Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a

Maréchal, D., Brault, V., Léon, A., Martin, D., Pereira, P. L., Loaëc, N., Birling, M., Friocourt, G., Blondel, M., & Hérault, Y. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddy447 · Cited by 56 · see citing works

Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice

Stagni, F., Giacomini, A., Guidi, S., Ciani, E., Ragazzi, E., Filonzi, M., IASIO, R. D., Rimondini, R., & Bartesaghi, R. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.12.005 · Cited by 53 · see citing works

Using C. elegans to Decipher the Cellular and Molecular Mechanisms Underlying Neurodevelopmental Disorders

Bessa, C., Maciel, P., & Rodrigues, A. J. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8434-6 · Cited by 50 · see citing works

Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome

Kleschevnikov, A. M., Yu, J., Kim, J., Lysenko, L. V., Zeng, Z., Yu, Y. E., & Mobley, W. C. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.03.009 · Cited by 46 · see citing works

DYRK1A-mediated phosphorylation of GluN2A at Ser1048 regulates the surface expression and channel activity of GluN1/GluN2A receptors

Grau, C. J. A., Arató, K., Fernández‐Fernández, J. M., Valderrama, A., Sindreu, C. B., Fillat, C., Ferrer, I., de la Luna, S., & Altafaj, X. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00331 · Cited by 46 · see citing works

Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits

Stringer, M., Goodlett, C. R., & Roper, R. J. (2017) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.334 · Cited by 44 · see citing works

Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice

Velázquez, R., Meechoovet, B., Ow, A., Foley, C., Shaw, A. Y., Smith, B. E., Oddo, S., Hulme, C., & Dunckley, T. L. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01684-9 · Cited by 43 · see citing works

Dyrk1a gene dosage in glutamatergic neurons has key effects in cognitive deficits observed in mouse models of MRD7 and Down syndrome

Brault, V., Nguyen, T. L., Gutiérrez, J. F., Iacono, G. L., Birling, M., Lalanne, V., Méziane, H., Manousopoulou, A., Pavlovic, G., Lindner, L., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009777 · Cited by 41 · see citing works

Stem and progenitor cell dysfunction in human trisomies

Liu, B., Filippi, S. L., Roy, A., & Roberts, I. A. G. (2014) · EMBO Reports · doi:10.15252/embr.201439583 · Cited by 42 · see citing works

Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B

Deau, E., Lindberg, M. F., Miege, F., Roche, D., George, N. S., George, P. G., Krämer, A., Knapp, S., & Meijer, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00884 · Cited by 42 · see citing works

Longitudinal measures of cognition in the Ts65Dn mouse: Refining windows and defining modalities for therapeutic intervention in Down syndrome

Olmos-Serrano, J. L., Tyler, W. A., Cabral, H., & Haydar, T. F. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.02.005 · Cited by 42 · see citing works

Multi-influential genetic interactions alter behaviour and cognition through six main biological cascades in Down syndrome mouse models

Duchon, A., Moreno, M. D. M. M., Lorenzo, S. M., de Souza, M. P. S., Chevalier, C., Nalesso, V., Méziane, H., de Sousa, P. L., Noblet, V., Armspach, J., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab012 · Cited by 38 · see citing works

CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation

Alldred, M. J., Chao, H. M., Lee, S. H., Beilin, J., Powers, B. E., Petkova, E., Strupp, B. J., & Ginsberg, S. D. (2018) · Hippocampus · doi:10.1002/hipo.22832 · Cited by 35 · see citing works

Genome-wide miR-155 and miR-802 target gene identification in the hippocampus of Ts65Dn Down syndrome mouse model by miRNA sponges

Ros, X. B., Santos, M., Vila-Casadesús, M., Villanueva, E., Andreu, N., Dierssen, M., & Fillat, C. (2015) · BMC Genomics · doi:10.1186/s12864-015-2160-6 · Cited by 33 · see citing works

Restoring neuronal chloride homeostasis with anti-NKCC1 gene therapy rescues cognitive deficits in a mouse model of Down syndrome

Parrini, M., Naskar, S., Alberti, M., Colombi, I., Morelli, G., Rocchi, A., Nanni, M., Piccardi, F., Charles, S., Ronzitti, G., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.023 · Cited by 33 · see citing works

Unbalanced dendritic inhibition of CA1 neurons drives spatial-memory deficits in the Ts2Cje Down syndrome model

Valbuena, S., García, Á., Mazier, W., Paternain, A. V., & Lerma, J. (2019) · Nature Communications · doi:10.1038/s41467-019-13004-9 · Cited by 32 · see citing works

Structure–Activity Relationship in the Leucettine Family of Kinase Inhibitors

Tahtouh, T., Durieu, É., Villiers, B., Bruyère, C., Nguyen, T. L., Fant, X., Ahn, K. H., Khurana, L., Deau, E., Lindberg, M. F., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01141 · Cited by 31 · see citing works

Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer’s Disease and Down Syndrome

Meijer, L., Chrétien, E., & Ravel, D. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240078 · Cited by 30 · see citing works

Bioinformatics analysis of biomarkers and transcriptional factor motifs in Down syndrome

Kong, X., Liu, N., & Xu, X. (2014) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20143792 · Cited by 28 · see citing works

Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome

Kazim, S. F., Blanchard, J., Bianchi, R., & Iqbal, K. (2017) · Scientific Reports · doi:10.1038/srep45561 · Cited by 28 · see citing works

HIV-1-Tat Protein Inhibits SC35-mediated Tau Exon 10 Inclusion through Up-regulation of DYRK1A Kinase

Kadri, F., Pacifici, M., Wilk, A. M., Struckhoff, A. P., Valle, L. D., Hauser, K. F., Knapp, P. E., Parsons, C. H., Jeansonne, D. P., Lassak, A., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.675751 · Cited by 26 · see citing works

Brain circuit pathology in Down syndrome: from neurons to neural networks

Bartesaghi, R. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0067 · Cited by 25 · see citing works

Developmental excitatory-to-inhibitory GABA polarity switch is delayed in Ts65Dn mice, a genetic model of Down syndrome

Lysenko, L. V., Kim, J., Madamba, F., Tyrtyshnaia, A. A., Ruparelia, A., & Kleschevnikov, A. M. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.03.005 · Cited by 21 · see citing works

Prioritizing the development of mouse models for childhood brain disorders

Ogden, K. K., Ozkan, E. D., & Rumbaugh, G. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.029 · Cited by 20 · see citing works

Plasticity as a therapeutic target for improving cognition and behavior in Down syndrome

Martínez‐Cué, C., & Dierssen, M. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.11.001 · Cited by 15 · see citing works

Structure-activity relationship for the folding intermediate-selective inhibition of DYRK1A

Miyazaki, Y., Kikuchi, M., Umezawa, K., Descamps, A., Nakamura, D., Furuie, G., Sumida, T., Saito, K., Kimura, N., Niwa, T., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113948 · Cited by 14 · see citing works

A dynamic in vitro model of Down syndrome neurogenesis with trisomy 21 gene dosage correction

Bansal, P., Banda, E. C., Glatt-Deeley, H. R., Stoddard, C. E., Linsley, J. W., Arora, N., Deleschaux, C., Ahern, D. T., Kondaveeti, Y., Massey, R. E., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj0385 · Cited by 13 · see citing works

Neuronal overexpression of Alzheimer's disease and Down's syndrome associated DYRK1A/minibrain gene alters motor decline, neurodegeneration and synaptic plasticity in Drosophila

Lowe, S. A., Usowicz, M. M., & Hodge, J. J. L. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.01.017 · Cited by 13 · see citing works

Hydroxyurea Improves Spatial Memory and Cognitive Plasticity in Mice and Has a Mild Effect on These Parameters in a Down Syndrome Mouse Model

Brose, R. D., Savonenko, A. V., Devenney, B., Smith, K. D., & Reeves, R. H. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00096 · Cited by 11 · see citing works

Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model

Hawley, L. E., Stringer, M., Deal, A. J., Folz, A., Goodlett, C. R., & Roper, R. J. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106359 · Cited by 10 · see citing works

Heterogeneous subpopulations of GABAAR-responding neurons coexist across neuronal network scales and developmental stages in health and disease

Colombi, I., Rastogi, M., Parrini, M., Alberti, M., Potenzieri, A., Chellali, M. M., Rosati, S., Chiappalone, M., Nanni, M., Contestabile, A., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109438 · Cited by 10 · see citing works

Enhanced GIRK2 channel signaling in Down syndrome: A feasible role in the development of abnormal nascent neural circuits

Kleschevnikov, A. M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1006068 · Cited by 9 · see citing works

Phosphoproteomic Alterations of Ionotropic Glutamate Receptors in the Hippocampus of the Ts65Dn Mouse Model of Down Syndrome

de Salazar, M. G., Grau, C. J. A., Ciruela, F., & Altafaj, X. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00226 · Cited by 8 · see citing works

GR/Ahi1 regulates WDR68-DYRK1A binding and mediates cognitive impairment in prenatally stressed offspring

Wei, B., Shi, H., Xi, Y., Shi, Y., Zeng, H., Zhao, Y., Zhao, Z., Song, Y., Sun, M., & Wang, B. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05075-1 · Cited by 8 · see citing works

Analysis of microisolated frontal cortex excitatory layer III and V pyramidal neurons reveals a neurodegenerative phenotype in individuals with Down syndrome

Alldred, M. J., Pidikiti, H., Ibrahim, K. W., Lee, S. H., Heguy, A., Hoffman, G. E., Roussos, P., Wısnıewskı, T., Węgiel, J., Stutzmann, G. E., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02768-0 · Cited by 7 · see citing works

Epigenetics and Down syndrome

González-Molina, L. A., Dekker, A. D., Deyn, P. P. D., Dolga, A. M., & Rots, M. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18516-8.00014-4 · Cited by 6 · see citing works

Intricacies of aging and Down syndrome

Kozlov, G., Franceschi, C., & Vedunova, M. V. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105794 · Cited by 6 · see citing works

The promise of cyclic AMP modulation to restore cognitive function in neurodevelopmental disorders

Bhattacharya, A., Turkalj, L., & Manzini, M. C. (2024) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2024.102966 · Cited by 6 · see citing works

The role of Goldilocks protein kinase DYRK1A in embryonic development

Johnson, H. K., Litovchick, L., & DICKINSON, A. J. G. (2025) · Developmental Biology · doi:10.1016/j.ydbio.2025.06.009 · Cited by 5 · see citing works

A Researcher’s guide to rodent models of Down syndrome: Recent insights and translational perspectives

Raza, M. A., Folz, A., Victorino, D. B., Xing, Z., Chen, X., Zuo, X., Borden, L. K., Potier, M., Mobley, W. C., Dierssen, M., et al. (2026) · STAR Protocols · doi:10.1016/j.xpro.2026.104717 · Cited by 5 · see citing works

New insights into the regulation of Cystathionine beta synthase (CBS), an enzyme involved in intellectual deficiency in Down syndrome

Conan, P., Léon, A., Caroff, N., Rollet, C., Chaïr, L., Martin, J., Bihel, F. J. ‐., Mignen, O., Voisset, C., & Friocourt, G. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1110163 · Cited by 5 · see citing works

Can Green Tea Polyphenols Improve Phenotypes Associated With Down Syndrome?

Roper, R. J., & Goodlett, C. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813008-7.00035-7 · Cited by 5 · see citing works

Synaptic Plasticity in the Hippocampus

Bliss, T., Collingridge, G. L., Cooke, S. F., Georgiou, J., & Morris, R. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780190065324.003.0010 · Cited by 4 · see citing works

Profiling hippocampal neuronal populations reveals unique gene expression mosaics reflective of connectivity-based degeneration in the Ts65Dn mouse model of Down syndrome and Alzheimer’s disease

Alldred, M. J., Ibrahim, K. W., Pidikiti, H., Lee, S. H., Heguy, A., Chiosis, G., Mufson, E. J., Stutzmann, G. E., & Ginsberg, S. D. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1546375 · Cited by 4 · see citing works

Insights into phosphoproteomic studies and prospects of phosphoproteins as biomarkers for brain disorders

Le, J., Hu, X., Jiang, Y., Wang, Q., Ma, Q., & Cui, W. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877251411546 · Cited by 1 · see citing works

Epigenetics and Down syndrome

Dekker, A. D., Deyn, P. P. D., & Rots, M. G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800226-1.00009-5 · Cited by 1 · see citing works

Ts65Dn synaptic proteome partially recapitulates AD biochemical signaturePreprint

de Salazar, M. G. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.25.538253 · Cited by 1 · see citing works

Cell Size Control in Fission Yeast

Pan, K. Z. (2013) · doi:10.7916/d8028zxf

Identification of New IRS1 Interactors in the Regulation of Insulin Signalling and Cell Proliferation

Frendo‐Cumbo, S. (2021) · TSpace (University of Toronto)

Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase‐1A (DYRK1A), A Master Regulatory Protein Involved in Down Syndrome Brain Alterations and Mental Disability, A Key Contributor to Neurodegenerative Disorders of Alzheimer's Disease and A Potential Therapeutic Target

Rachidi, M. (2022) · International Journal of Neurodegenerative Disorders · doi:10.23937/2643-4539/1710023

Defective engram allocation contributes to impaired fear memory performance in Down syndromePreprint

Fernández‐Blanco, Á., Zamora‐Moratalla, A., Sabariego-Navarro, M., & Dierssen, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.11.523460

Heterogeneous subpopulations of GABAAR-responding neurons coexist in physiological and pathological mature neuronal networks at increasing scales of complexityPreprint

Colombi, I., Rastogi, M., Parrini, M., Alberti, M., Chiappalone, M., Nanni, M., Contestabile, A., & Cancedda, L. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.25.542321

DYRK1A (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A), a Master Regulatory Protein Involved in Down Syndrome Clinical Neurological Abnormalities and Associated Mental Retardation and a Promising Potential Drug Target for Therapeutics and Treatments

Rachidi, M. (2023) · Medical Journal of Clinical Trials & Case Studies · doi:10.23880/mjccs-16000347

Correction des déficits cognitifs chez des modèles murins de trisomie 21 par un inhibiteur de la kinase DYRK1A : étude pharmacologique et mécanistique

Nguyen, T.-L. (2017) · doi:10.70675/37ec63a1z9652z4b2czbff5zc55c5d157bbe

Longitudinal analysis of brain networks by magnetic resonance imaging (MRI) in a murine model of neuropathic pain-induced depression

Karatas, M. (2019) · theses.fr (ABES) · doi:10.70675/9f5ffcc1z2dfcz4157z8ce5z05964b6bfedf

BindingDB Entry 50016614: Structure-activity relationship for the folding intermediate-selective inhibition of DYRK1A.

BindingDB (2023) · UC San Diego · doi:10.7270/q26h4nfv

BindingDB Entry 50020201: Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B.

BindingDB (2024) · UC San Diego · doi:10.7270/q26m3c7h

BindingDB Entry 50016416: Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors.

BindingDB (2023) · UC San Diego · doi:10.7270/q2fn1b7v

Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and Neuromorphological alterations found in a mouse model of down syndrome

García-Cerro, S., Martínez, P., Vidal, V., Corrales, A., Flórez, J., Vidal, R., Rueda, N., Arbonés, M. L., & Martínez-Cué, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106572 · Cited by 104 · see citing works

Normalizing the gene dosage of Dyrk1A in a mouse model of down syndrome rescues several Alzheimer’s disease phenotypes

García-Cerro, S., Rueda, N., Vidal, V., Lantigua, S., & Martínez-Cué, C. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.06.010 · Cited by 100 · see citing works

Data from: Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome

García-Cerro, S., Martinez, P. M., Vidal, V., Corrales, A., Flórez, J., Vidal, R., Rueda, N., Arbonés, M. L., & Martínez‐Cué, C. (2014) · Data Archiving and Networked Services (DANS) · doi:10.5061/dryad.p5614

Preclinical Treatment of Neurobehavioral and Brain Structural Deficits in the Ts65Dn Down Syndrome Mouse Model with a Novel Dyrk1a Inhibitor

Whiteside, J. A., & Stringer, M. (2018) · Digital Commons @ Butler University (Butler University)

DYRK1A Dynamics: The Influence of Gene Copy Number on Neurodevelopment in the Ts65Dn Mouse Model of Down Syndrome

Hawley, L. E. (2024) · IUScholarWorks (Indiana University) · doi:10.25394/pgs.25620741